- “Trinity Biotech’s blood-clot analyzer gets FDA nod” (Reuters)
- “Teva Provides Update on Generic Ortho Tri-Cyclen(R) Lo” (Press release issued by Teva Pharmaceutical Industries, Ltd., Trading Markets)
- “GlaxoSmithKline drug protects against cancer-causing viruses” (Hays Pharma)
- “Good News for Sanofi-Aventis: Heart Drug Multaq Receives FDA Approval” (Seeking Alpha)
- “Mylan: FDA approved generic prostate cancer drug” (Business Week)
- “All Fifty States to Screen Newborns for Cystic Fibrosis by 2010” (Press release issued by the Cystic Fibrosis Foundation, PRNewsWire)
- “BioScrip Selected to Participate in Teva Neuroscience MS Research Study” (Press release issued by BioScrip, Inc. and Teva Neuroscience, Trading Markets)
- “Teva and Antares Get FDA Approval of Needle-Free Injector Product” (Press release issued by Teva Neuroscience and Antares Pharma Inc, Trading Markets)
- “GSK says Cervarix effective against more viruses” (Reuters)
- “Pozen Submits NDA for Vimovo (PN 400)” (Trading Markets)
- “Novartis commits to reducing TB in Tanzania” (PharmacyEurope)
- “XenoPort Reveals Results from a Phase 2 Trial of Arbaclofen Placarbil“(Press release issued by XenoPort, Inc., Trading Markets)
- “King and Pain Therapeutics Announce REMOXY(R) NDA Update” (Press release issued by King and Pain Therapeutics, PRNewsWire)
THE LATEST WORD
Top Industry Stories – July 7, 2009
Posted on July 7th, 2009 | by Rxmedyn | No Comments »Posted in Industry Stories
SUBSCRIBE-
Recent Posts
Archives
Careers | © 2009 Medical Dynamics